SYS-CON MEDIA Authors: Gilad Parann-Nissany, Kevin Benedict, Unitiv Blog, Mark R. Hinkle, Glenn Rossman

News Feed Item

MiMedx to Present at the 13th Annual Needham Healthcare Conference

MARIETTA, Ga., March 28, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent  protected  regenerative  biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, April 8th at 3:00 p.m. EDT, at the Westin NY Grand Central Hotel.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.

Needham & Company's 13th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

 

SOURCE MiMedx

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.